Skip to main content

Table 1 Characteristics of the included studies

From: Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis

Study Study type Study period Population No. of patients Mean age (year) Clinical presentation Treatment Testing time Testing standard Definition of HTPR Definition of LTPR
Ticagrelor Prasugrel Ticagrelor Prasugrel
Alexopoulos 2014 [8] cohrot study NR ACS undergoing PCI T: 278 (232/46) T: 60.6 ± 11.8 STEMI: 154 STEMI: 130 90 mg bid MD 10 mg MD 1 month post discharge PRU PRU > 208 NR
NSTEMI: 63
P: 234 (200/34) P: 58.4 ± 10.2 NSTEMI: 69 UA: 41
UA: 55
Alexopoulos 2012 [7] RCT NR ACS and HTPR patients undergoing PCI T: 22 (19/3) T: 61.3 ± 8.1 STEMI: 8 STEMI: 11 90 mg bid, 15 days 10 mg QD, 15 days 15 days of treatment PRU PRU ≥ 235 NR
NSTEMI: 7 NSTEMI: 3
P: 22 (18/4) P: 58.3 ± 8.6 UA: 8
UA: 7
Alexopoulos 2013 [9] RCT 2012.06–2012.09 ACS patients with DM T: 15 (14/1) T: 65.4 ± 7.7 STEMI: 3 STEMI: 4 90 mg bid, 15 days 10 mg QD, 15 days 15 days of treatment PRU PRU ≥ 230 NR
NSTEMI: 7 NSTEMI: 4
P: 15 (14/1) P: 60.9 ± 8.0 UA: 7
UA: 5
Deharo 2013 [11] RCT 2013.03–2013.06 patients admitted for ACS 96 (78/18) 60.8 ± 9.8 NR NR 90 mg bid 10 mg QD 1 month after ACS PRI VASP PRI VASP≥50% PRI VASP ≤20%
T: 48; P: 48
Deharo 2014 [12] RCT 2013.03–2013.12 patients admitted for ACS T: 93; P: 93 NR NR NR 90 mg bid 10 mg QD 1 month after ACS PRI VASP PRI VASP≥50% PRI VASP ≤20%
Dillinger 2014 [13] cohrot study NR consecutive patients admitted for ACS T: 119 59 NR NR NR NR during the hospitalization for ACS PRI VASP NR VASP-PRI < 16%
P: 268
Franchi 2016 [14] RCT 2014.03–2015.10 underwent PCI in the setting of an ACS T-M: 27 (20/7) T-M: 57 ± 7 NR NR T-M: 90 mg bid MD 10 mg QD MD 1 week after randomization PRU PRU > 208, PRI > 50% NR
T: 54.8 ± 10.5 PRI-VASP
T: 25 (21/4)
P: 57 ± 6.9
P: 27 (21/6)
Guimaraes 2017 [28] RCT 2013.07–2015.12 Patients with STEMI T: 25 (18/7) T: 52.2 ± 8.1 STEMI STEMI 90 mg MD bid 60 mg LD 24 h after inclusion PRU NR NR
P: 55.5 ± 8.3
P: 25 (22/3)
Kerneis 2015 [15] cohrot study NR Patients with STEMI underwent PCI T: 58 (49/9) T: 59.97 ± 1.54 STEMI STEMI 90 mg MD bid 10 mg MD QD 30 d after primary PCI PRU, VASP-PRI VASP-PRI > 50%, VASP-PRI < 16%
PRU < 85
P: 60 (49/11) P: 57.78 ± 1.37 PRU > 208
Laine 2014 [16] RCT 2012.10–2013.02 DM patients undergoing PCI for an ACS T: 50 (33/17) T: 64.8 ± 8.9 STEMI or NSTEMI: 41 STEMI/NSTEMI: 40 180 mg LD, 90 mg BID MD 60 mg LD, 10 mg QD MD 6–18 h post-LD VASP VASP> 50 and 61% VASP< 16%
P: 62.8 ± 8.2
P: 50 (43/7) UA: 10
UA: 9
Laine 2015 [17] RCT 2012.08–2013.06 STEMI patients with ongoing ischemia admitted for primary PCI T: 44 (40/4) T: 57.4 ± 9.8 STEMI STEMI 180 mg LD 60 mg LD 6-12 h after the LD and before the first MD VASP VASP≥50% VASP< 16%
P: 54.7 ± 8.3
P: 44 (37/7)
lhermusier 2014 [18] RCT 2012.11–2013.06 Patients admitted for ACS T: 10 (10/0) T:75(70–78) NR NR 90 mg bid 10 mg bid 24 h ± 4 after inclusion PRU, PRI- VASP PRU ≥ 208 NR
PRI ≥50%
P: 10 (9/1) P: 64 (52–68)
Parodi 2013 [19] RCT NR STEMI patients undergoing primary PCI T: 25 (19/6) T: 67 ± 10 STEMI STEMI 180 mg LD 60 mg LD 2 h after LD PRU PRU ≥240 NR
P: 67 ± 14
P: 25 (20/5)
Yudi 2016 [21] cohort study 2009.07–2013.11 consecutive ACS patients T: 526 (411/115) T: 61.7 ± 11.8 STEMI: 288 STEMI: 230 NR NR NR NR NR NR
NSTEMI: 138
P: 368 (317/51) P: 57.1 ± 9.7 NSTEMI: 238
  1. Abbreviations: RCT randomized controlled trial, ACS acute coronary syndrome, PCI percutaneous coronary intervention, DM Diabetes Mellitus, STEMI ST segment elevation myocardial infarction, NSTEMI non ST segment elevation myocardial infarction, UA unstable angina, CAD coronary artery disease, HTPR high on-treatment platelet reactivity, LTPR low on-treatment platelet reactivity, T ticagrelor, P prasugrel, bid twice a day, QD once a day, MD maintenance dose, LD loading dose, VASP-PRI vasodilator-stimulated phosphoprotein platelet reactivity index, PRU P2Y12 reaction units, NR not reported